Guangdong Jiaying Pharmaceutical Co., Ltd Stock

Equities

002198

CNE1000008P1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-30 pm EDT 5-day change 1st Jan Change
6.45 CNY +0.94% Intraday chart for Guangdong Jiaying Pharmaceutical Co., Ltd +0.16% -11.40%
Sales 2022 659M 90.98M Sales 2023 533M 73.6M Capitalization 3.69B 510M
Net income 2022 43M 5.93M Net income 2023 34M 4.69M EV / Sales 2022 4.66 x
Net cash position 2022 236M 32.57M Net cash position 2023 336M 46.34M EV / Sales 2023 6.3 x
P/E ratio 2022
75.3 x
P/E ratio 2023
108 x
Employees -
Yield 2022 *
-
Yield 2023
0.69%
Free-Float 64.29%
More Fundamentals * Assessed data
Dynamic Chart
Guangdong Jiaying Pharmaceutical Co., Ltd Approves Cash Dividend for the Year 2023 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Announcement of Resolutions of Guangdong Jiaying?s Fifth Extraordinary General Meeting of Shareholders in 2021 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangdong Jiaying Pharmaceutical Co., Ltd. Approves Management Appointments CI
Resolutions on Supervisor Nomination by Guangdong Jiaying Venture Capital CI
Guangdong Jiaying Venture Capital Submits Proposals Related to Supervisor Nominations CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangzhou Taiping Enterprise Management Partnership (Limited Partnership) signed the Share Transfer Agreement to acquire 5% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Chen Shaobin for approximately CNY 195 million. CI
Jiaying Pharma Sees Up to 3,420% Surge in 2022 Profit MT
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day+0.94%
1 week+0.16%
1 month-1.53%
3 months+8.77%
6 months-14.11%
Current year-11.40%
More quotes
1 week
6.21
Extreme 6.21
6.54
1 month
6.08
Extreme 6.08
7.10
Current year
4.67
Extreme 4.67
7.43
1 year
4.67
Extreme 4.67
9.15
3 years
4.42
Extreme 4.42
11.00
5 years
3.92
Extreme 3.92
11.00
10 years
3.92
Extreme 3.92
20.88
More quotes
Managers TitleAgeSince
Director of Finance/CFO 38 21-10-14
Chairman 67 21-08-01
Director/Board Member 43 11-12-31
Members of the board TitleAgeSince
Director/Board Member 61 19-05-15
Director/Board Member 61 21-05-30
Director/Board Member 44 21-07-31
More insiders
Date Price Change Volume
24-05-31 6.45 +0.94% 4,163,655
24-05-30 6.39 -.--% 3,244,013
24-05-29 6.39 +2.24% 6,165,344
24-05-28 6.25 -3.25% 5,771,766
24-05-27 6.46 +0.31% 5,960,301

End-of-day quote Shenzhen S.E., May 30, 2024

More quotes
GUANGDONG JIAYING PHARMACEUTICAL CO., LTD is a China-based company principally engaged in the research, development, manufacture and sales of Chinese patent medicine. The Company’s main products include Chinese traditional preparations, powders, tablets, capsules and granules, which are mainly applied in the treatment of throat disease, cold, stomach disease and others, as well as for tonic nourish purpose and others. The Company distributes its products mainly in domestic market. Through its subsidiaries, the Company is also engaged in the operation and leasing of self-owned real estate.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002198 Stock